Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape.

59 Collectively, 126 patients (56 SVd, 70 Vd) had RI (CrCl <40 or 40-60 ml/min): mPFS was significantly improved with SVd compared with Vd (CrCl 40-60 ml/min: 16.62 versus 7.26 months; CrCl <40 ml/min: 7.62 versus 4.30 months); also, in terms of OS, patients with RI showed a trend in favor of SVd (median: not reached in both ≤40 ml/min and 40-60 ml/min) versus Vd (median: 19.06 months for <40 ml/min; 21.22 months for 40-60 ml/min).

also in 53,322 other papers